Viking Therapeutics EPS VKTX
Diluted earnings per share by quarter and over the last twelve months, from 2014.
- Last 12 months, to Sep 30, 2026
- −$5.40
- Latest quarter, Q3 FY26
- −$1.55
- Fiscal year 2025
- −$3.18
Viking Therapeutics' earnings per share was −$5.40 over the twelve months to Sep 30, 2026.
In its latest quarter, Q3 FY26, it was −$1.55.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$3.18 | n/a |
| FY2024 | −$1.00 | n/a |
| FY2023 | −$0.92 | n/a |
| FY2022 | −$0.91 | n/a |
| FY2021 | −$0.72 | n/a |
| FY2020 | −$0.54 | n/a |
| FY2019 | −$0.36 | n/a |
| FY2018 | −$0.41 | n/a |
| FY2017 | −$0.80 | n/a |
| FY2016 | −$1.00 | n/a |
| FY2015 | −$4.01 | n/a |
| FY2014 | −$5.25 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q3 FY26 | −$1.55 | n/a | −$5.40 | |
| Q2 FY26 | −$1.10 | n/a | −$4.66 | |
| Q1 FY26 | −$1.37 | n/a | −$4.14 | |
| Q4 FY25 | −$1.38 | n/a | −$3.18 | |
| Q3 FY25 | −$0.81 | n/a | −$2.12 | |
| Q2 FY25 | −$0.58 | n/a | −$1.53 | |
| Q1 FY25 | −$0.41 | n/a | −$1.15 | |
| Q4 FY24 | −$0.32 | n/a | −$1.00 | |
| Q3 FY24 | −$0.22 | n/a | −$0.93 | |
| Q2 FY24 | −$0.20 | n/a | −$0.94 | |
| Q1 FY24 | −$0.26 | n/a | −$0.93 | |
| Q4 FY23 | −$0.25 | n/a | −$0.92 |
Against its peers
Companies in Drug Manufacturers - General nearest Viking Therapeutics' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| VKTXViking Therapeutics | −$5.40 | |
| OGNOrganon | $0.76 | −60% a year |
| LQDALiquidia | $1.39 | |
| ARQTArcutis Biotherapeutics | $0.22 | |
| NRIXNurix Therapeutics | $2.31 | |
| INDVIndivior Pharmaceuticals | $3.57 | +250% a year |
| PBHPrestige Consumer Healthcare | $3.57 | −16% a year |
| HRMYHarmony Biosciences | $3.09 | −0% a year |
| LGNDLigand Pharmaceuticals | $9.40 | |
| AMRXAmneal Pharmaceuticals | $0.49 | +4800% a year |
| KNSAKiniksa Pharmaceuticals International | $0.97 | +2325% a year |
| Peer median | $1.85 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Viking Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.